共 50 条
- [2] Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon- like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes DIABETES OBESITY & METABOLISM, 2017, 19 (02): : 200 - 207
- [4] Glucagon-like peptide-1 levels and dipeptidyl peptidase-4 activity in type 2 diabetes CLINICAL AND INVESTIGATIVE MEDICINE, 2017, 40 (05): : E188 - E199
- [5] Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (< 50 years) obese patients with type 2 diabetes mellitus JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2014, 1 (02): : 31 - 37
- [6] Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function Endocrine, 2016, 51 : 429 - 439
- [7] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes LANCET, 2006, 368 (9548): : 1696 - 1705
- [9] Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? DIABETES OBESITY & METABOLISM, 2018, 20 (08): : 1937 - 1943